APA

Gourdeau H., Bibeau L., Ouellet F., Custeau D., Bernier L. & Bowlin T. (20010503). Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. : Cancer chemotherapy and pharmacology.

Chicago

Gourdeau H, Bibeau L, Ouellet F, Custeau D, Bernier L and Bowlin T. 20010503. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. : Cancer chemotherapy and pharmacology.

Harvard

Gourdeau H., Bibeau L., Ouellet F., Custeau D., Bernier L. and Bowlin T. (20010503). Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. : Cancer chemotherapy and pharmacology.

MLA

Gourdeau H, Bibeau L, Ouellet F, Custeau D, Bernier L and Bowlin T. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. : Cancer chemotherapy and pharmacology. 20010503.